scholarly journals Highly sensitive nucleic acid detection and transaminase level in treatment decisions for Chinese patients with cirrhosis caused by hepatitis

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052095921
Author(s):  
Yue-Rong Zhang ◽  
Hui Wang ◽  
Yao-Di Zhang ◽  
Yan Lin ◽  
Li-Yang Wu ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Nucleic Acid ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Chinese Patients ◽  
Youden Index ◽  
Nucleic Acid Detection ◽  
Hcv Rna ◽  
Operating Characteristics ◽  
Highly Sensitive

Objective To explore the usefulness of highly sensitive nucleic acid detection for assisting with the accurate antiviral treatment of patients with cirrhosis that was caused by hepatitis. Methods There were 377 patients with hepatitis B with cirrhosis and 119 patients with hepatitis C with cirrhosis, either as hospitalized patients and outpatients, who were enrolled into the study. Among them, 299 were men and 197 were women between 23 and 82 years of age. All patients were examined using a domestic HBV DNA/HCV RNA test, which was negative in 162 cirrhosis with hepatitis B and 54 cirrhosis with hepatitis C patients (HBV DNA/HCV RNA <500 IU/mL). Prediction and analysis of the HBV DNA load using alanine aminotransferase (ALT) level was based on receiver operating characteristics (ROC) curve analysis. Results For patients with hepatitis C with cirrhosis, after the antiviral therapy, ALT, HCV RNA, and Child–Pugh grade were significantly improved compared with before treatment. ROC analysis results showed that an ALT level of 29 IU/mL was the most sensitive cutoff value to judge a positive HBV DNA load (sensitivity 1.0, specificity 0.237, Youden index 0.763). Conclusion Precise detection for patients with cirrhosis caused by hepatitis is required for accurate therapy.

scholarly journals A211 SPONTANEOUS HBV REMISSION AFTER HBV REACTIVATION FOLLOWING TREATMENT WITH SOFOSBUVIR AND VELPATASVIR IN A PATIENT WITH HCV AND HBV CO-INFECTION: CASE REPORT

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 242-243
Author(s):  
A Chiang ◽  
K Tsoi
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Antiviral Agents ◽  
Clinical Signs ◽  
Hbv Dna ◽  
Hcv Rna ◽  
Hbv Reactivation ◽  
Genotype 3 ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background In co-infected patients with hepatitis B (HBV) and hepatitis C (HCV), the treatment of HCV with direct-acting antiviral agents (DAA) can cause HBV reactivation. However, there are no clear guidelines on the timing of treatment initiation, especially in the absence of clinical signs of flare. Aims Here we discuss the case of a 34-year-old female with HBV and HCV genotype 3 who had HBV reactivation following HCV treatment, but did not require nucleos(t)ide therapy. Methods She initially presented with chronic inactive hepatitis B and chronic hepatitis C with HBV DNA level of 67.5 IU/mL and HCV RNA level of 3.33 x 106 IU/mL. She completed a 12 week course of sofosbuvir and velpatasvir for HCV and achieved sustained virologic remission, but subsequently developed reactivation of her HBV with HBV DNA peaking at 3.41 x 104 IU/mL twelve weeks post-treatment. She did not develop any signs of hepatitis and a decision was made to monitor her clinically. Results Two years later, she spontaneously went into remission with her HBV DNA levels being &lt;10 IU/mL. Conclusions The significance of this case is to illustrate HBV reactivation following treatment of HCV with DAAs may not necessitate immediate treatment, especially if there are no signs of flare. There have been similar reported cases, but larger prospective studies are required to determine the appropriate clinical context where monitoring may be acceptable instead of immediate treatment. Funding Agencies None

scholarly journals Effect of Multiple Freeze-Thaw Cycles on Hepatitis B Virus DNA and Hepatitis C Virus RNA Quantification as Measured with Branched-DNA Technology

1999 ◽  
Vol 37 (6) ◽  
pp. 1683-1686 ◽  
Author(s):  
Mel Krajden ◽  
James M. Minor ◽  
Oretta Rifkin ◽  
Lorraine Comanor
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Hcv Rna ◽  
Freeze Thaw ◽  
Rna Quantification ◽  
B Virus ◽  
Rna Levels

Quantification of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA often is performed in specimens that have been frozen and thawed more than once. To ensure optimal therapeutic and prognostic value, it is important to establish whether viral load measurements are affected by repeated freeze-thaw (FT) cycles. We therefore evaluated the effect of multiple FT cycles on HBV DNA and HCV RNA quantification by testing serum specimens subjected to one (baseline), two, four, and eight FT cycles with the appropriate Chiron Quantiplex assay. Linear regression analysis showed minor increases of 1.7% per FT cycle for both HBV DNA and HCV RNA. The rise in HCV RNA levels was more pronounced among low-concentration samples, since further analysis revealed an increase of 3.2% per FT cycle among samples with 0.2 to 3.86 Meq of HCV RNA per ml. Given that the coefficient of variation for the Quantiplex assays is generally 10 to 15%, the minor increases in HBV DNA and HCV RNA levels with progressive FT cycles for the specimens tested were recognized only because analysis of variance revealed a statistically significant trend (P < 0.05). Due to the minor statistical trend, the clinical impact for individual patient specimens is likely to be limited, but it may deserve further study. In conclusion, the concentration of HBV DNA and HCV RNA in serum specimens subjected to up to eight short-term FT cycles was stable.

scholarly journals Hepatitis B and Hepatitis C Viral Infections in Patients with Chronic Lymphocytic Leukemia

2014 ◽  
Vol 28 (3) ◽  
pp. 131-134 ◽  
Author(s):  
Gerald Y Minuk ◽  
Betty Lerner ◽  
Spencer B Gibson ◽  
James B Johnston ◽  
Julia Uhanova ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Chronic Lymphocytic Leukemia ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Lymphocytic Leukemia ◽  
Core Antigen ◽  
Hcv Rna ◽  
Occult Hbv ◽  
Mutational Status ◽  
Chronic Hepatitis B Virus

BACKGROUND: Whether chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections contribute to the pathogenesis and/or course of chronic lymphocytic leukemia is unclear.OBJECTIVE: To document the prevalences of HBV and HCV infections in chronic lymphocytic leukemia patients, and to determine whether infected patients experience more aggressive disease than those without infection.METHODS: Patient sera were screened for antibodies to HBV core antigen and HCV (anti-HCV) using ELISA; both sera and peripheral blood lymphocytes were further tested (regardless of antibody results) for HBV-DNA and HCV-RNA using real-time polymerase chain reaction. Prognostic markers for chronic lymphocytic leukemia included Rai stage,IgVHmutational status, β2-microglobulin levels, Zap-70 and CD38 status.RESULTS: Fourteen of 222 (6.3%) chronic lymphocytic leukemia patients and two of 72 (2.8%) healthy controls tested positive for previous or ongoing HBV infection (OR 2.4 [95% CI 0.5 to 7.7]; P=0.25) while four of 222 (1.8%) chronic lymphocytic leukemia patients and one of 72 (1.4%) controls tested positive for HCV markers (OR 1.3 [95% CI 0.2 to 6.4]; P=0.81). The levels and distribution of the various indicators of aggressive chronic lymphocytic leukemia disease were similar among HBV- and HCV-infected and uninfected patients. Survival times were also similar. Occult HBV and HCV infection (HBV-DNA or HCV-RNA positive in the absence of diagnostic serological markers) were uncommon in chronic lymphocytic leukemia patients (0.5% and 1.8%, respectively).CONCLUSIONS: The results of the present study do not support the hypothesis that HBV or HCV infections play an important role in the pathogenesis or course of chronic lymphocytic leukemia.

Diagnostik der Hepatitis B und C

Praxis ◽  
2005 ◽  
Vol 94 (3) ◽  
pp. 66-72
Author(s):  
Moradpour ◽  
Blum
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Sensitivität Und Spezifität ◽  
Hcv Rna ◽  
Antivirale Therapie

Die Diagnose der Hepatitis B und C kann heute mit hoher Sensitivität und Spezifität durch einfache und kostengünstige serologische Tests gesichert werden. Als Suchtests werden HBsAg bzw. anti-HBc für die Hepatitis B und anti-HCV für die Hepatitis C eingesetzt. Im Hinblick auf eine antivirale Therapie und für das Monitoring unter Therapie sind der Nachweis von HBeAg bzw. HBV DNA bei der Hepatitis B und die Bestimmung des Genotyps sowie der qualitative bzw. quantitative Nachweis der HCV RNA bei der Hepatitis C heute Standard. Eine Leberbiopsie zur Objektivierung des Entzündungsgrades und des Fibrosestadiums ist bei der Hepatitis C im Hinblick auf eine antivirale Therapie indiziert.

scholarly journals Association of Vitamin D Deficiency with Hepatitis B and C Virus Infection

2021 ◽  
pp. 10-14
Author(s):  
Darshan Kumar ◽  
Muhammad Umar Khan ◽  
Syed Mohammad Kashif ◽  
Majid Ahmed Shaikh ◽  
Zunaira Nawaz ◽  
...  
Keyword(s):  
Vitamin D ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis B ◽  
Vitamin D Deficiency ◽  
Large Scale ◽  
Hbv Dna ◽  
Hcv Rna ◽  
Serological Tests ◽  
Vitamin D Levels

Objective: To evaluate the association of vitamin D deficiency with hepatitis B and C virus Infection. Study Design: This is a prospective study. Setting: Study carried out at Medicine department Civil Hospital Karachi, from March, 2018 to December, 2019. Materials and Methods:  266 Participants of the study included patients with active hepatitis B or hepatitis C infection visiting OPD of the hospital. Vitamin D levels of 14-30 ng/ml have been described as insufficient and levels <14 ng/ml are labelled as deficient. Vitamin D level of >30 nm/ml have been defined as sufficient according to our study. Diagnosis of Hepatitis B is confirmed by HBV DNA and HBsAg serum levels and of Hepatitis C by HCV RNA levels. Results: We received 70.6% (n=266) males and 29.3% females. After serological tests 34.9% (n=93) patients were positive for HBV DNA whereas 47.7% (n=127) patients were positive for HCV DNA. Coinfection with hepatitis B and C was present in 17.2% (n=46) of patients. Amongst total 266 participants 54.31% patients have been vitamin D deficient and 32.7% have insufficient vitamin D levels. Conclusion: Genetic and metabolic factors linked to hepatitis B and C with vitamin D deficiency should be studied on large scale. In our study patients infected with HBV and HCV have been vitamin D deficient, supplementation needs to be added to the treatment regimen.

Occult hepatitis B and occult hepatitis C viremia in patients with hematologic malignancies.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17016-e17016
Author(s):  
Harrys A. Torres ◽  
Parag Mahale ◽  
Dimitrios P Kontoyiannis ◽  
F. Blaine F. Blaine Hollinger
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Liver Dysfunction ◽  
Hbv Dna ◽  
Hcv Rna ◽  
Dna Testing ◽  
Severe Liver ◽  
Occult Hepatitis ◽  
Occult Hepatitis B ◽  
Severe Liver Dysfunction

e17016 Background: Occult Hepatitis B (OHB)and Hepatitis C (OHC) in patients with hematological malignancies (HM) are understudied, mainly because biopsies to identify these viruses in the liver are often not performed due to an associated risk of complications (e.g., bleeding). We describe our retrospective experience of patients with HM tested for OHB and OHC. Methods: Between 09/09 and 11/10, 18 unselected consecutive patients with an abnormal liver panel were tested for both OHB and OHC which was defined as detectable viremia in the absence of HBsAg and anti-HCV, respectively. Severe liver dysfunction was defined as ALT >10 times the upper limit of normal (>560 IU/L) and/or a total bilirubin >6 mg/dL. Plasma samples were tested for HBV DNA and HCV RNA by using real-time PCR (Cobas Taqman HBV and HCV Tests-Roche Molecular Systems). Results: Most patients (12 or 67%) had leukemia, followed by lymphoma (5 patients or 28%). Two patients (11%) had OHB, and none had OHC.The 2 patients with OHB were born in areas with an intermediate to high prevalence of HBV; both had only low grade viremia (<29 IU/mL). At the time HBV DNA testing was performed, peak ALT levels in these 2 patients were 843 IU/L and 6,047 IU/L compared to a median peak ALT of 302 IU/L (range, 84-1,320 IU/L) among those without OHB (P=0.03). Severe liver dysfunction occurred in the 2 (100%) patients with OHB compared to 6 (38%) of the non-OHB cases (P=0.1). Durations of ALT elevation were 12 and 17 days in patients with OHB, compared to a median duration of 13 days (range, 5-73 days) in non-OHB patients. Co-infections were identified in 1 patient with OHB and in 10 (63%) without OHB. The 2 patients with OHB and 8 (50%) patients without OHB died within 6 months after HBV DNA testing. Conclusions: Although our data are limited, in a group of cancer patients in whom a liver biopsy is not available, detection of HBV DNA or HCV RNA in serum in the absence of HBsAg or anti-HCV identifies a subset of patients with occult viral hepatitis, a phenomenon of unclear clinical significance.

The prevalence of hepatitis B and C co-infections among people with HIV-1 in Bulgaria: 2010–2015

2019 ◽  
Vol 14 (12) ◽  
pp. 791-798
Author(s):  
Ivailo Alexiev ◽  
Elitsa Golkocheva-Markova ◽  
Asya Kostadinova ◽  
Reneta Dimitrova ◽  
Lora Nikolova ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Hcv Rna ◽  
B Virus ◽  
Sex With Men ◽  
Multiple Risk Behavior ◽  
Hiv 1 ◽  
Hiv Aids

Aim: To evaluate hepatitis B virus (HBV) and hepatitis C virus (HCV) among individuals with HIV/AIDS in Bulgaria diagnosed between 2010 and 2015. Materials & methods: A total of 1158 individuals were diagnosed with HIV/AIDS during the study period. Different transmission groups were tested with ELISA and real-time PCR for HBV and HCV markers. Results: Hepatitis B surface antigen and hepatitis C virus antiboby were found in 9.3 and 23.2% of the tested. HBV DNA and HCV RNA has been found in 47.4 and 69.6%. Hepatitis B and C co-infections were predominant in multiple risk behavior groups, including people who inject drugs, men who have sex with men, prisoners and Roma individuals. Conclusion: HIV prevalence in Bulgaria is low but the rates of hepatitis B and C co-infections among these patients fall within the upper range reported in Europe.

Sign in / Sign up

Export Citation Format

Share Document